JP2009507835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507835A5 JP2009507835A5 JP2008530022A JP2008530022A JP2009507835A5 JP 2009507835 A5 JP2009507835 A5 JP 2009507835A5 JP 2008530022 A JP2008530022 A JP 2008530022A JP 2008530022 A JP2008530022 A JP 2008530022A JP 2009507835 A5 JP2009507835 A5 JP 2009507835A5
- Authority
- JP
- Japan
- Prior art keywords
- neuritin
- composition
- antibody
- vector
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 101710189685 Neuritin Proteins 0.000 claims 39
- 102100028749 Neuritin Human genes 0.000 claims 39
- 239000013598 vector Substances 0.000 claims 20
- 239000005557 antagonist Substances 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 210000003289 regulatory T cell Anatomy 0.000 claims 14
- 108020001507 fusion proteins Proteins 0.000 claims 12
- 102000037865 fusion proteins Human genes 0.000 claims 12
- 101000577555 Homo sapiens Neuritin Proteins 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 230000002519 immonomodulatory effect Effects 0.000 claims 5
- 102000007079 Peptide Fragments Human genes 0.000 claims 4
- 108010033276 Peptide Fragments Proteins 0.000 claims 4
- 108091008103 RNA aptamers Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 101000577556 Mus musculus Neuritin Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000004073 interleukin-2 production Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000699660 Mus musculus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000011813 knockout mouse model Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71576605P | 2005-09-09 | 2005-09-09 | |
| PCT/US2006/035324 WO2007030820A2 (en) | 2005-09-09 | 2006-09-11 | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013239723A Division JP6019334B2 (ja) | 2005-09-09 | 2013-11-20 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009507835A JP2009507835A (ja) | 2009-02-26 |
| JP2009507835A5 true JP2009507835A5 (cg-RX-API-DMAC7.html) | 2009-11-05 |
Family
ID=37836580
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530022A Pending JP2009507835A (ja) | 2005-09-09 | 2006-09-11 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
| JP2013239723A Active JP6019334B2 (ja) | 2005-09-09 | 2013-11-20 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
| JP2016083897A Pending JP2016183163A (ja) | 2005-09-09 | 2016-04-19 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
| JP2018089059A Pending JP2018197227A (ja) | 2005-09-09 | 2018-05-07 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013239723A Active JP6019334B2 (ja) | 2005-09-09 | 2013-11-20 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
| JP2016083897A Pending JP2016183163A (ja) | 2005-09-09 | 2016-04-19 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
| JP2018089059A Pending JP2018197227A (ja) | 2005-09-09 | 2018-05-07 | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100040636A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3031470A3 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2009507835A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006287315B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2621992C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007030820A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2719267A1 (en) * | 2008-04-25 | 2009-10-29 | New York Blood Center, Inc. | Abi1/hssh3bp1 conditional knockout mouse |
| WO2012135842A2 (en) * | 2011-03-31 | 2012-10-04 | President And Fellows Of Harvard College | A unique population of regulatory t cells that regulate tissue regeneration and wound healing |
| US20150258096A1 (en) * | 2012-10-10 | 2015-09-17 | The Regents Of The University Of California | Methods and compositions for treatment of th2-mediated and th17-mediated diseases |
| EP3404116B1 (en) * | 2013-03-15 | 2022-10-19 | The University of Chicago | Methods and compositions related to t-cell activity |
| KR101941004B1 (ko) * | 2013-03-25 | 2019-01-23 | 주식회사 엘지화학 | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 |
| WO2016049085A1 (en) * | 2014-09-23 | 2016-03-31 | Oregon Health & Science University | APTAMER-RNAi THERAPEUTIC COMPOSITIONS |
| US12076369B2 (en) | 2017-09-01 | 2024-09-03 | The Frances Crick Institute Limited | Immunoregulatory molecules and uses therefor |
| WO2020146772A1 (en) * | 2019-01-11 | 2020-07-16 | The Johns Hopkins University | Neuritin regulation of t cell anergy and t regulatory cell function |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| WO1987001130A1 (en) | 1985-08-15 | 1987-02-26 | Stauffer Chemical Company | Tryptophan producing microorganism |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| AU633958B2 (en) | 1989-07-25 | 1993-02-11 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5180940A (en) | 1990-02-09 | 1993-01-19 | Asulab S.A. | Radial field electrostatic micromotor produced using a photolithographic micromanufacturing technique and a process for producing said micromotor |
| ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| TW304957B (cg-RX-API-DMAC7.html) | 1991-06-18 | 1997-05-11 | Lilly Co Eli | |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5817784A (en) * | 1996-08-09 | 1998-10-06 | Amgen Inc. | Neurogene |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| JP2003524406A (ja) * | 1999-06-02 | 2003-08-19 | ジェネンテック・インコーポレーテッド | 腫瘍細胞成長阻害のための組成物及び方法 |
| AU2002363231A1 (en) * | 2001-10-29 | 2003-05-12 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
| US20040176291A1 (en) * | 2002-09-24 | 2004-09-09 | Elly Nedivi | Methods and compositions for soluble CPG15 |
| EP1585482A4 (en) * | 2002-09-25 | 2009-09-09 | Genentech Inc | NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS |
| WO2004062591A2 (en) * | 2003-01-06 | 2004-07-29 | Oregon Health And Science University | Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases |
| EP1715889A4 (en) * | 2004-01-08 | 2008-03-05 | Univ California | LYMPHOCYTES T REGULATORS SUPPRESSING AUTOIMMUNITY |
-
2006
- 2006-09-11 EP EP16152994.6A patent/EP3031470A3/en active Pending
- 2006-09-11 CA CA2621992A patent/CA2621992C/en active Active
- 2006-09-11 US US11/991,693 patent/US20100040636A1/en not_active Abandoned
- 2006-09-11 WO PCT/US2006/035324 patent/WO2007030820A2/en not_active Ceased
- 2006-09-11 EP EP06814458A patent/EP1931384A4/en not_active Withdrawn
- 2006-09-11 AU AU2006287315A patent/AU2006287315B2/en active Active
- 2006-09-11 JP JP2008530022A patent/JP2009507835A/ja active Pending
-
2013
- 2013-11-20 JP JP2013239723A patent/JP6019334B2/ja active Active
-
2016
- 2016-04-19 JP JP2016083897A patent/JP2016183163A/ja active Pending
-
2018
- 2018-05-07 JP JP2018089059A patent/JP2018197227A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seyfrid et al. | CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment | |
| Tran et al. | Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia | |
| JP6683990B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Goddard et al. | Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies | |
| JP7696658B2 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞 | |
| JP2021151249A (ja) | 腫瘍抗原ｎｙ−ｅｓｏ−１のｍｈｃ ｉおよびｍｈｃ ｉｉ拘束性エピトープに対する、癌の併用ｔ細胞受容体遺伝子療法 | |
| WO2021147121A1 (zh) | 修饰的免疫细胞及其应用 | |
| JP2019516352A (ja) | Ｆｌｔ３に対するキメラ受容体及びその使用方法 | |
| JP6942466B2 (ja) | 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法 | |
| CN114174495A (zh) | 肿瘤浸润淋巴细胞疗法及其用途 | |
| ES2967879T3 (es) | Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9 | |
| CN110627909A (zh) | 一种特异性活化nk细胞的嵌合抗原受体及其应用 | |
| Bandara et al. | Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7 | |
| JP2022512922A (ja) | キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法 | |
| JP2018531016A6 (ja) | 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 | |
| Look et al. | CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines | |
| Martins et al. | EphA3 CAR T cells are effective against glioblastoma in preclinical models | |
| CN107523548A (zh) | 一种高效稳定表达抗体的t细胞及其用途 | |
| He et al. | Intravenous senescent erythrocyte vaccination modulates adaptive immunity and splenic complement production | |
| WO2018082590A1 (zh) | 肿瘤免疫治疗靶标及其应用 | |
| JP2009507835A5 (cg-RX-API-DMAC7.html) | ||
| Deuse et al. | Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells | |
| WO2017035251A1 (en) | T cells modified to overexpress c-myb | |
| WO2024017362A1 (zh) | 靶向gprc5d和/或bcma的嵌合抗原受体及其应用 | |
| CN112262212B (zh) | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 |